At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...
Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...
Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...
The company might bend, but it won't break.
Merck, known as MSD outside the U.S. and Canada, is restructuring its Human Health organization and appointing three new ...
Merck (MRK) announced plans to separate its core pharmaceutical division into two units as it prepares for the upcoming patent expiration of its top-selling drug. The drugmaker said it is organizing ...
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results